In patients with estrogen
receptor (ER)-positive/HER2-negative breast cancer, PET/CT may be more useful
than MRI for monitoring tumor response to neoadjuvant chemotherapy, according
to a new report. The investigators, at the Netherlands Cancer Institute, in
Amsterdam, wanted to evaluate whether one screening method might be more
effective than the other depending on the breast cancer subtype (PLoS ONE 2017;12[5]:e0176782, PMID:
28531188).
For the study, the investigators enrolled 188